Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Research & Development: 2023-2024

Historic Research & Development for CG Oncology (CGON) over the last 2 years, with Dec 2024 value amounting to $82.1 million.

  • CG Oncology's Research & Development rose 42.11% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.5 million, marking a year-over-year increase of 58.40%. This contributed to the annual value of $82.1 million for FY2024, which is 79.45% up from last year.
  • Latest data reveals that CG Oncology reported Research & Development of $82.1 million as of FY2024, which was up 79.45% from $45.8 million recorded in FY2023.
  • In the past 5 years, CG Oncology's Research & Development registered a high of $82.1 million during FY2024, and its lowest value of $45.8 million during FY2023.
  • Over the past 2 years, CG Oncology's median Research & Development value was $63.9 million (recorded in 2023), while the average stood at $63.9 million.
  • Data for CG Oncology's Research & Development shows a peak YoY spiked of 79.45% (in 2024) over the last 5 years.
  • CG Oncology's Research & Development (Yearly) stood at $45.8 million in 2023, then spiked by 79.45% to $82.1 million in 2024.